Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term FAILURE. Found 5 abstracts

Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EE, Cheung MR, Lee AK, Pollack A. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. International Journal of Radiation Oncology Biology Physics. 2008 Jan;70(1):67-74.
Marks DI, Perez WS, He W, Zhang MJ, Bishop MR, Bolwell BJ, Bredeson CN, Copelan EA, Gale RP, Gupta V, Hale GA, Isola LM, Jakubowski AA, Keating A, Klumpp TR, Lazarus HM, Liesveld JL, Maziarz RT, McCarthy PL, Sabloff M, Schiller G, Sierra J, Tallman MS, Waller EK, Wiernik PH, Weisdorf DJ. Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood. 2008 Jul;112(2):426-34.
Trabulsi EJ, Valicenti RK, Hanlon AL, Pisansky TM, Sandler HM, Kuban DA, Catton CN, Michalski JM, Zelefsky MJ, Kupelian PA, Lin DW, Anscher MS, Slawin KM, Roehrborn CG, Forman JD, Liauw SL, Kestin LL, DeWeese TL, Scardino PT, Stephenson AJ, Pollack A. A Multi-Institutional Matched-Control Analysis of Adjuvant and Salvage Postoperative Radiation Therapy for pT3-4N0 Prostate Cancer. Urology. 2008 Dec;72(6):1298-302.
Chen XW, Wilson RM, Kubo H, Berretta RM, Harris DM, Zhang XY, Jaleel N, MacDonnell SM, Bearzi C, Tillmanns J, Trofimova I, Hosoda T, Mosna F, Cribbs L, Leri A, Kajstura J, Anversa P, Houser SR. Adolescent feline heart contains a population of small, proliferative ventricular myocytes with immature physiological properties. Circulation research. 2007 Mar;100(4):536-44.
Valicenti RK, DeSilvio M, Hanks GE, Porter A, Brereton H, Rosenthal SA, Shipley WU, Sandler HM, Haile RW, Thomas DC, McGuire V, Felberg A, John EM, Milne RL, Hopper JL, Jenkins MA, Levine AJ, Daly MM, Buys SS, Senie RT, Andrulis IL, Knight JA, Godwin AK, Southey M, McCredie MR, Giles GG, Andrews L, Tucker K, Miron A, Apicella C, Tesoriero A, Bane A, Pike MC, Whittemore AS. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: An analysis of radiation therapy oncology group protocol 92-02 BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE prostate cancer; prostate-specific antigen doubling time; mortality; surrogate endpoint. 2006 Oct;15(10):1863-70.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term FAILURE

FAILURE TRIAL RADICAL PROSTATECTOMY the risk of dying requirements for a surrogate endpoint of CSS Thus surrogate endpoint prostate cancer PCR but did not meet all of Prentice's significantly associated with CSS IRRADIATION NONCARRIERS THERAPY (T2c-4 and PSA level < 150 ng ALLOGENEIC TRANSPLANTATION MYOCARDIAL REGENERATION DEATH we tested if PSADT was prognostic and Cox proportional hazards model CALCIUM-CHANNELS TOXICITY the randomized treatment (Conclusions) under bar Prostatic specific antigen doubling time is ERA (P-Cox = 04) The significant posttreatment PSADTs were also EPIDEMIOLOGY dose 2ND COMPLETE REMISSION radiotherapy HISTORY CONFORMAL RADIOTHERAPY RISK BIOCHEMICAL CONTROL CARDIAC STEM-CELLS CA2+ CHANNELS independent of randomized treatment in this cohort The endpoints were RADIOTHERAPY T-type calcium current new ventricular myocytes-cardiac stem cells-calcium external beam significant predictors of CSS (P-Cox < 0001) After adjusting for T OVARIAN-CANCER randomized RISK AB (Purpose:) under bar We evaluated whether posttreatment Gleason score and PSA stage-all of Prentice's requirements were not (Methods and Materials: ) under bar We analyzed posttreatment PSA 78 GY WOMEN time to PSADT (assuming first-order kinetics for a minimum of 3 rising REGISTRY on Radiation Therapy Oncology Group Protocol 92-02 From June 1992 to or in combination with 24 65-70 Gy of radiation therapy (n = 761) PSADT < 6 months (pc < 0001) 0002)-PSADT < 9 months (P-Cox < indicating that the effect of PSADT on CSS was not independent of met of prostate cancer is not fully explained by PSADT (c) 2006 Elsevier and PSADT < 12 months (P-Cox < 0001) but not for PSADT < 3 0001) PATTERNS HYPERTROPHY randomized treatment was a significant predictor for CSS (p(Cox) = GENE months of adjuvant androgen deprivation (n = 753) Using an adjusted EFFICACY CELL-DERIVED CARDIOMYOCYTES SURVIVAL men were randomized to neoadjuvant androgen deprivation and April 1995 RTOG Inc SARCOPLASMIC-RETICULUM BIOPSY prostatic-specific antigen doubling time (PSADT) was predictive of prostate cancer mortality by testing the Prentice requirements for a (Results: ) under bar After a median follow-up time of 59 years CARCINOMA PSA measurements) and cancer-specific survival (CSS) RADIATION-THERAPY MEN IN-VITRO MORTALITY IMPACT EORTC STEM-CELL TRANSPLANTATION DIFFERENTIATION 514 men with localized prostate cancer measurements in a cohort of 1 ADENOCARCINOMA treated and monitored prospectively mL) RECURRENCE BONE-MARROW-TRANSPLANTATION CHILDREN
Last updated on Thursday, July 09, 2020